Monday, Johnson & Johnson (NYSE:JNJ) said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.
Following an Independent Data Monitoring Committee recommendation and pre-specified interim analysis, SunRISe-2 was discontinued for not showing superiority versus chemoradiation.
“We remain confident in the TARIS platform having over $5 billion potential,” Johnson & Johnson notes.
Data from the SunRISe-4 study recently presented at the 2024 European Society for Medical Oncology Congress show the potential of TAR-200 in MIBC.
Also Read: Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization.
The company says it is on target for the FDA filing of TAR-200 monotherapy (SunRISe-1) in non-muscle invasive bladder cancer in ...